Latest news with #WST
Metro
2 days ago
- Sport
- Metro
2025 Shanghai Masters Snooker schedule, how to watch, prize money and odds
The Shanghai Masters gets underway on Monday at the Luwan Gymnasium, with the world's best snooker players battling it out for the prestigious title. The top 16 in the world make it into the Shanghai Masters and they are joined by the four highest ranked Chinese players outside that elite group, plus four local wildcards. Judd Trump lifted the trophy last season, beating Shaun Murphy in the final and the world number one will be looking to claim back-to-back titles. Ronnie O'Sullivan had made the event his own before Trump's victory last year, winning four editions of the Shanghai Masters on the spin. There is no shortage of contenders for the silverware, including new world champion Zhao Xintong, who will be playing for the first time since his Crucible triumph. The likes of Kyren Wilson, Mark Selby, John Higgins and Ding Junhui have all tasted success in Shanghai before and would love to replicate that on Sunday. One change to the draw since it was made saw Ali Carter replace Mark Allen as the Northern Irishman withdrew due to personal reasons. The tournament runs from July 28 – August 3. Monday July 28 (UK times) Round One02.30: Si Jiahui vs Wang Xinbo02.30: Barry Hawkins vs Wu Yize07.00: Zhang Anda vs Yuan Sijun07.00: Chris Wakelin vs Zhou Jinhao12.30: Neil Robertson vs Pang Junxu 12.30: Shaun Murphy vs Han Fuyuan Tuesday July 29 02.30: Xiao Guodong vs Lei Peifan 02.30: Ali Carter vs Qiu Lei Round Two07.00: Mark Selby vs Murphy/Han07.00: Kyren Wilson vs Si/Wang12.30: Judd Trump vs Robertson/Pang 12.30: Ding Junhui vs Zhang/Yuan Wednesday July 3007.00: John Higgins vs Xiao/Lei07.00: Mark Williams vs Carter/Qiu12.30: Ronnie O'Sullivan vs Hawkins/Wu 12.30: Zhao Xintong vs Wakelin/Zhou The tournament is being shown on TNT Sports and discovery+ in the UK. Winner £210,000Runner-up £105,000Semi-finals £70,000Quarter-finals £35,000Last 16 £17,500Last 24 £10,000 High break £10,000 Judd Trump 16/5Zhao Xintong 9/2Kyren Wilson 6/1Ronnie O'Sullivan 6/1Mark Selby 8/1John Higgins 10/1Ding Junhui 11/1Mark Williams 12/1Neil Robertson 14/1Shaun Murphy 16/1Ali Carter 22/1Si Jiahui 25/1Xiao Guodong 25/1Chris Wakelin 25/1Barry Hawkins 25/1Zhang Anda 40/1Wu Yize 40/1Yuan Sijun 50/1Pang Junxu 125/1Lei Peifan 125/1Zhou Jinhao 500/1Qiu Lei 500/1 Wang Xinbo500/1 Odds courtesy of Betfair 'I started off firing against Mark Williams and I got better as the tournament went on,' the defending champion told WST. 'It was probably one of the best performances I've ever produced in a whole event. Nobody really got close to me that week. 'It sets you up for the whole season. When you get off to a quick start it puts you in a good position. I then won in Saudi straight away after. You are so relaxed after getting the first win. This is important for everyone. It is the first event that all of the top players enter. You don't know what to expect as you aren't match sharp. But it is important to put the work in so you come out strongly.' Non-ranking event 2024 Judd Trump2023 Ronnie O'Sullivan2019 Ronnie O'Sullivan 2018 Ronnie O'Sullivan Ranking event 2017 Ronnie O'Sullivan2016 Ding Junhui2015 Kyren Wilson2014 Stuart Bingham2013 Ding Junhui2012 John Higgins2011 Mark Selby2010 Ali Carter2009 Ronnie O'Sullivan2008 Ricky Walden 2007 Dominic Dale MORE: Championship League Snooker: 10 things we learned from a month at the Mattioli MORE: Resurgent Stephen Maguire tinkers his way to first title in five years MORE: Stephen Hendry challenges snooker star to bounce back from 'disappointing' season
Bloomberg
5 days ago
- Business
- Bloomberg
Stock Movers: West Pharma, Chipotle, Southwest
On this edition of Stock Movers: - West Pharmaceutical Services (WST) shares advanced as much as 28%, a record one-day climb, after the maker of packaging components for the drug industry boosted its adjusted profit and net sales outlook for the full year. - Chipotle Mexican Grill (CMG) shares plunged after cutting its annual outlook for the second time this year, suggesting that honey chicken and burrito giveaways haven't been enough to offset a traffic slump that the company attributed to economic anxiety. Sales at established restaurants are now expected to be about flat for the full year, the company said Wednesday. It previously forecast the metric would expand by a low-single digit. The shares tumbled as much as 14% in New York, their biggest intraday drop since March 2020. The stock was down 12% this year through Wednesday's close, among the worst performers in US restaurants. Chipotle had already cut its annual guidance earlier this year after economic uncertainty, among other factors, dinged results. - Southwest Airlines (LUV) shares fell after the carrier said it expects economic turmoil to wipe out as much as $1 billion of its annual pre-tax profit this year and offered shareholders a much-reduced outlook for the balance of 2025. Earnings before interest and taxes for the year will be $600 million to $800 million, Southwest said in a statement on Wednesday that also included second-quarter results that fell short of analyst expectations. The carrier originally expected $1.7 billion in pre-tax profit at the start of the year. Southwest is one of a few companies so far to put a price on the fallout from President Donald Trump's efforts to reset global trade, inflation and economic uncertainty that caused travel demand to collapse early this year. Most carriers pulled financial guidance in April, saying it was impossible to forecast demand.
Metro
6 days ago
- Sport
- Metro
Stephen Hendry challenges snooker star to bounce back from disappointing season
Stephen Hendry feels Mark Allen needs a good season after a disappointing campaign last time round, challenging the Pistol to get back to his trophy-winning best. The Northern Irishman did not have a disastrous season by any means, winning the non-ranking Riyadh Season Snooker Championship in December, but it was not his best and he admitted being frustrated with his game in the second half of the campaign. It got to the stage in March that his confidence was so low that he said he didn't want to qualify for the upcoming Players Championship, which only features the top 16 players on the one-year ranking list. The fact he did qualify for that event shows that it was not a calamitous campaign, but a first round defeat and then a second round loss at the World Championship rounded off an underwhelming campaign. The 39-year-old has 11 ranking titles to his name, five of which came in the last three years but none last season, and Hendry has called on him to rediscover the form of the recent past. 'I'd be interested to see Mark Allen this year. He had a disappointing season last year, for him,' Hendry said on WST's Snooker Club podcast. 'After the couple of seasons before becoming a serial winner, picking up a lot of silverware. 'I'm not saying he's going to struggle or drop out of the top 16 or anything drastic like that, but I think he needs to get back and get a good season.' Steven Hallworth, professional player, commentator and pundit, feels that Allen is searching too much for the answer to his form problems and should get back to basics. 'He did a lot of tinkering with different coaches and I see him at a couple of events on the practice table doing things that didn't look like they really suited him and I think he just lost his way a little bit,' said Hallworth. 'If he can get rid of that and go back to just potting balls and playing the game that we all know he can then I think he'll be alright.' 2024 Players Championship 2023 Snooker Shoot Out 2023 World Grand Prix 2022 UK Championship 2022 Northern Ireland Open 2021 Northern Ireland Open 2018 Scottish Open 2018 International Championship 2016 Players Tour Championship Finals 2013 World Open 2012 World Open Allen actually went to Hendry for advice last season as he looked for a boost to his game and felt it had helped him after a good first round win at the Crucible over Fan Zhengyi. 'I spoke to Stephen Hendry after I lost in the Players Championship,' he explained after beating Fan in Sheffield. 'Just asked him if he had any advice. He said: 'Take yourself away for a few days and don't bog yourself down on the practice table.' 'I've never done that in my career ever. Never mid-season have I gone away, other than between Christmas and New Year. It's always been the way I've worked. 'I feel like if I'm missing a day of practice I deserve to not play well the next day. I feel guilty for taking days off. But he pushed me down the road of taking a few days off and literally overnight I booked a flight to Dubai just thought about nothing snooker-related at all for a few days. 'I came back a little bit fresher and hit the ground running on the practice table, which was good.' Allen is enjoying plenty of time off over the summer as he is yet to play a match and has pulled out of the upcoming Shanghai Masters for personal reasons. 'I would have loved to play in Shanghai but I'm not able to make it this year for family reasons,' he said. 'I'd like to apologise to the fans, our partners in Shanghai and my sponsors Liberwin and Omin as I have always enjoyed playing in this fantastic event. I'll be working hard to make sure I'm in it next season.' More Trending One player Hendry does expect to shine next season is someone who has been relentlessly consistent for years now, Judd Trump. Asked who he expects to win more tournaments than anyone else this season, the seven-time world champion quickly backed the world number one. 'I think Trump again,' he said. 'I think he's still at the peak of his career. He's a winning machine. It's very, very difficult to make a case for anyone else than Trump this year.' MORE: Ronnie O'Sullivan outlines ambitious plan for after he retires from snooker MORE: Jordan Brown hit 'extreme low' and considered quitting snooker before making vital decision MORE: Chris Wakelin: A massive part of me thought I'd win the World Championship
Yahoo
22-07-2025
- Business
- Yahoo
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
West Pharmaceutical Services WST is scheduled to release second-quarter 2025 results on July 24, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 18.85%. WST's earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 7.81%. Q2 Estimates Per management, the company expects second-quarter revenues to be in the range of $720 million to $730 million, implying a 3% to 4% organic sales growth. Also, second-quarter adjusted diluted earnings per share (EPS) are expected to be in the range of $1.50 to $1.55. Currently, the Zacks Consensus Estimate for revenues is pegged at $726 million, indicating growth of 3.4% from the year-ago period's level. The consensus mark for earnings is pinned at $1.51 per share, indicating a decline of 0.7% year over year. Our model estimates total revenues to be $722.2 million, implying a 3.2% organic improvement year over year. The adjusted EPS is estimated to be $1.50. While the Proprietary Products segment sales are anticipated to be $583.5 million (organic growth of 4.6%), Contract-Manufactured Products segmental sales are likely to be $138.7 million. Operating profit for the Proprietary Products segment is likely to improve 6.8% whereas for the Contract-Manufactured Products segment, operating profit is likely to decline 14.2%. Factors to Note West Pharmaceutical delivered a solid first-quarter performance in 2025, beating both revenue and earnings expectations. With reported revenues of $698 million and earnings per share (EPS) of $1.45, the company demonstrated resilience despite industry-wide destocking challenges. As the company is poised to post second-quarter results, a segmental analysis suggests a mix of continued growth and stabilization, supported by strategic investments in high-value products (HVPs), contract manufacturing and biologics. In the Proprietary Products segment, West is heading into the second quarter with solid demand trends, particularly for high-value offerings like GLP-1-related components and self-injection platforms. HVPs made up more than 73% of segment revenues in the first quarter, driven by continued strength in GLP-1s. The company is working through a short-term capacity constraint at one facility due to a shift in customer sourcing, which may affect near-term volumes. Pricing came in slightly softer than expected, but not materially so. While some early-quarter challenges could influence growth pacing, management remains confident in a steady pickup in volumes as the year unfolds. Biologics, a key sub-segment within Proprietary Products, is likely to show a mixed but stable performance in the second quarter. The SmartDose platform continued to gain traction in the first quarter, and that momentum is expected to carry into the second quarter as well. However, investors should be mindful that incentive-related comparisons from the back half of 2024 could temper growth in the coming quarters. High-value component volumes in Biologics remained soft due to ongoing destocking trends, and while a more meaningful recovery is anticipated later this year, the second quarter may still reflect some of that gradual normalization. On a positive note, Annex 1 contributed more than expected in the first quarter, benefiting from favorable timing, and while that early lift may normalize in coming periods, the growing project pipeline signals a steady tailwind through the rest of the year. In Contract Manufacturing, WST is navigating a deliberate shift in portfolio dynamics, as growth in GLP-1 auto-injectors helps offset volume declines tied to the wind-down of continuous glucose monitoring (CGM) contracts. This balancing act is expected to remain a theme through the second quarter, with revenue likely to trend stable while the mix continues to evolve. A key part of this transformation is the Dublin facility, which began early-stage commercial production earlier this year and is expected to expand its role over time. The site is being positioned not only for device manufacturing but also as a launchpad for drug-handling capabilities, which WST sees as a natural extension of its expertise. While utilization is still in its early stages, the company indicated that onboarding new drug-handling projects, which come with more attractive margin profiles and lower capital intensity, is progressing as planned. As these programs ramp, they should help smooth out transitional pressures and support a more profitable growth trajectory for the segment in the periods ahead. However, West Pharmaceutical's second-quarter performance is likely to reflect continued macro pressures and inventory-related dynamics, particularly in Biologics. A softer mix of lower-margin delivery devices and reduced volumes in high-margin HVP components may have weighed slightly on gross margins, though operational efficiencies and disciplined cost management likely provided some offset. The company remains focused on long-term margin improvement through automation, including progress toward its new SmartDose production line. West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise West Pharmaceutical Services, Inc. price-consensus-eps-surprise-chart | West Pharmaceutical Services, Inc. Quote What the Zacks Model Unveils Our proven model predicts an earnings beat for WST this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is exactly the case here, as you will see below. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.57%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #2 at present. Other Stocks Worth a Look Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time: GeneDx Holdings WGS has an Earnings ESP of +5.26% and a Zacks Rank #2. The company is slated to release second-quarter 2025 results on July 29. WGS' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 145.82%. The Zacks Consensus Estimate for the company's second-quarter EPS is expected to increase 190.9% from the year-ago quarter figure. Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2. The company is set to release third-quarter fiscal 2025 results on Aug. 6. COR's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. The Zacks Consensus Estimate for COR's fiscal third-quarter EPS is expected to surge 13.2% from the year-ago reported figure. Cardinal Health CAH has an Earnings ESP of +0.81% and a Zacks Rank #2. The company is slated to release fourth-quarter fiscal 2025 results on Aug. 12. CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%. The Zacks Consensus Estimate for the company's fiscal fourth-quarter EPS is expected to increase 10.3% from the year-ago quarter figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Irish Sun
15-07-2025
- Sport
- The Irish Sun
World Seniors Snooker DOUBLES prize money for 2025-26 and announces major rule change making Ronnie O'Sullivan eligible
RONNIE O'SULLIVAN is eligible to play on the World Seniors Snooker Tour next season following a big rule change. 1 Ronnie O'Sullivan will be eligible to play on the World Seniors Snooker Tour next season Credit: PA But he will now be eligible to play on the Seniors Tour, along with every other player aged 40 or over. Nine tour events will take place in the 2025/26 season. The winner's cheque will be doubled each weekend to £1,000 with prize money paid down to the last 16. Last season a prize pot of £50,000 was paid out in the World Seniors Snooker Championship, with winner Alfie Burden picking up £20,000. READ MORE IN SNOOKER Jason Francis, Chairman of WSS, said: 'This season there are a lot more players eligible to play, including a number of WST professionals, and we have pledged £27,000 in prize money across our nine events which is more than double the amount that was on offer last season. 'If you are over 40, now is the time to dust off your cue and come and enjoy some friendly but serious competition.' The first tournament of the new season takes place between August 15-17. The season runs until April, with a month's break between December 14 and January 16. Most read in Snooker CASINO SPECIAL - BEST CASINO BONUSES FROM £10 DEPOSITS A Super Seniors event will also take place on the Sunday of each weekend for players aged 55 or over. Championship League snooker match awkwardly interrupted by Ice Cream Van
